Background There is no strong evidence that any drug is beneficial either for the treatment of SARS-CoV-2 disease or for post-exposure prophylaxis. Therefore, clinical research is crucial to generate results and evaluate strategies against COVID-19. Primary care (PC) centers, the first level of care in the health system, are in a favorable position to carry out clinical trials (CD), as they work with a large volume of patients with varied profiles (from acute to chronic pathologies). During the COVID-19 pandemic, the need for hospital admission and mortality is higher in people > 60 years. Therefore, this is a target population to try to reduce the serious complications and lethality of COVID pneumonia and to avoid overloading the hospital system. Given the pharmacological properties of colchicine (anti-inflammatory and anti-fibrotic, possible inhibition of viral replication, and inhibitory effect on coagulation activation), early treatment with colchicine may reduce the rate of death and serious pulmonary complications from COVID-19 in vulnerable patients. Methods The COLCHICOVID study is a randomized, multicenter, controlled, open-label parallel group (2:1 ratio), phase III clinical trial to investigate the efficacy of early administration of colchicine in reducing the development of severe pulmonary complications associated with COVID-19 infection in patients over 60 years of age with at-risk comorbidities. Discussion This is a pragmatic clinical trial, adapted to usual clinical practice. The demonstration that early administration of colchicine has clinical effectiveness in reducing the complications of SARS-CoV-2 infection in a population highly susceptible may mitigate the health crisis and prevent the collapse of the health system in the successive waves of the coronavirus pandemic. In addition, colchicine is a well-known medicine, simple to use in the primary care setting and with a low cost for the health system. Trial registration ClinicalTrials.gov NCT04416334 . Registered on 4 June 2020. Protocol version: v 3.0, dated 22 September 2020.
【저자키워드】 coronavirus, Primary Health Care, early treatment, Colchicine, No hospitalized, 【초록키워드】 COVID-19, Treatment, Efficacy, coronavirus, primary care, clinical trial, pandemic, Mortality, Open-label, Anti-inflammatory, Pneumonia, SARS-COV-2 infection, COVID-19 pandemic, hospital, Infection, Comorbidities, clinical trials, Clinical research, Health crisis, Coagulation, Prophylaxis, Randomized, Health, Viral, COVID-19 infection, viral replication, early treatment, Research, Patient, death, Complication, clinical effectiveness, age, Colchicine, Hospital admission, COVID pneumonia, health system, multicenter, Pathologies, Care, Clinical practice, Evidence, Pragmatic, lethality, target population, level of care, Volume, SARS-CoV-2 disease, Activation, Trial registration, parallel group, profile, pulmonary complications, inhibitory effect, demonstration, early administration, successive waves, vulnerable patients, collapse, pharmacological, mitigate, susceptible, Prevent, serious complication, evaluate, addition, generate, reducing, reduce, pulmonary complication, successive wave, with COVID-19, 【제목키워드】 SARS-CoV-2, coronavirus, Study protocol, Coronavirus pneumonia, Randomized, Health, Patient, Effectiveness, Colchicine, administration, high risk, Controlled clinical trial, pulmonary complication,